Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis.


Journal

Acta gastro-enterologica Belgica
ISSN: 1784-3227
Titre abrégé: Acta Gastroenterol Belg
Pays: Belgium
ID NLM: 0414075

Informations de publication

Date de publication:
Historique:
entrez: 18 1 2020
pubmed: 18 1 2020
medline: 14 2 2020
Statut: ppublish

Résumé

Although multiple HCV prevalence studies were recently performed in the general population from Belgium, they suffer from a lack of geographical representativeness, an insufficient number of participants or a lack of inclusion of high prevalence groups. The aim of this study is to provide robust information on the HCV burden. Recently performed HCV prevalence studies in the general, adult population were included in this study, based on well-defined selection criteria. A meta-analysis was performed to estimate the seroprevalence, the prevalence of participants with viremia and the prevalence estimation for people with viremia which were unaware of their status. Eight studies fulfilled the criteria for inclusion of the quantitative prevalence estimation. Based on the meta-analysis on these 8 studies, we estimated an HCV seroprevalence of 1.01% [95% CI : 0.66-1.42%], representing a total of 90,722 adult, HCV seropositives of which 64,412 individuals (0.71%) were confirmed seropositive. Based on the RNA presence, an estimated viremic prevalence of 0.33% [95% CI : 0.21-0.47 %] was determined, corresponding with 29,642 individuals. This is 46,0% of the true HCV seropositive residents. Further, based on the availability of patient information in 5 out of the 8 studies, a prevalence of 0.18% [95% CI : 0.07-0.33] representing 16,168 individuals from the adult Belgian population are unaware of their HCV status. We believe that the quantitative measurement by the meta-analysis will be more reliable for their use in the design of a screening strategy or in the development of prevention campaigns as compared to the prevalence estimations performed at local level.

Sections du résumé

BACKGROUND AND STUDY AIMS OBJECTIVE
Although multiple HCV prevalence studies were recently performed in the general population from Belgium, they suffer from a lack of geographical representativeness, an insufficient number of participants or a lack of inclusion of high prevalence groups. The aim of this study is to provide robust information on the HCV burden.
METHODS METHODS
Recently performed HCV prevalence studies in the general, adult population were included in this study, based on well-defined selection criteria. A meta-analysis was performed to estimate the seroprevalence, the prevalence of participants with viremia and the prevalence estimation for people with viremia which were unaware of their status.
RESULTS RESULTS
Eight studies fulfilled the criteria for inclusion of the quantitative prevalence estimation. Based on the meta-analysis on these 8 studies, we estimated an HCV seroprevalence of 1.01% [95% CI : 0.66-1.42%], representing a total of 90,722 adult, HCV seropositives of which 64,412 individuals (0.71%) were confirmed seropositive. Based on the RNA presence, an estimated viremic prevalence of 0.33% [95% CI : 0.21-0.47 %] was determined, corresponding with 29,642 individuals. This is 46,0% of the true HCV seropositive residents. Further, based on the availability of patient information in 5 out of the 8 studies, a prevalence of 0.18% [95% CI : 0.07-0.33] representing 16,168 individuals from the adult Belgian population are unaware of their HCV status.
CONCLUSIONS CONCLUSIONS
We believe that the quantitative measurement by the meta-analysis will be more reliable for their use in the design of a screening strategy or in the development of prevention campaigns as compared to the prevalence estimations performed at local level.

Identifiants

pubmed: 31950802

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-485

Informations de copyright

© Acta Gastro-Enterologica Belgica.

Auteurs

G Muyldermans (G)

Sciensano, Brussels, Belgium.

R Bielen (R)

Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium.

R Botterman (R)

Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium.

S Bourgeois (S)

Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium.

I Colle (I)

Department of Hepatology and Gastroenterology and Intensive Care Unit, Algemeen Stedelijk Ziekenhuis, Aalst, Belgium.

B Deressa (B)

Hepatogastroenterology Department, CHU Brugmann Brussels, Belgium.

G Devolder (G)

Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium.

Y Horsmans (Y)

Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Belgium.

V Hutse (V)

Sciensano, Brussels, Belgium.

N Lanthier (N)

Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Belgium.

L Lasser (L)

Hepatogastroenterology Department, CHU Brugmann Brussels, Belgium.

S Platteau (S)

Department of Hepatology and Gastroenterology and Intensive Care Unit, Algemeen Stedelijk Ziekenhuis, Aalst, Belgium.

G Robaeys (G)

Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium.
Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Herestraat 49, 3000 Leuven, Belgium.

V Suin (V)

Sciensano, Brussels, Belgium.

X Verhelst (X)

Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium.

H Van Vlierberghe (H)

Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium.

L Van Baelen (L)

Sciensano, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH